Focus Partners Advisor Solutions, LLC
Position in IKT — Inhibikase Therapeutics, Inc.
CIK 1868872
SAINT LOUIS, MO
Position in IKT
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$19,968
-$2,005 QoQ
Shares Held
11,886
+10.9% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in IKT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Focus Partners Advisor Solutions, LLC holds $11,279,306 across 23 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
28,722 | $3,255,925 | |
| 2 | EXEL |
Exelixis, Inc.
|
26,603 | $1,447,469 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,165 | $1,349,964 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,708 | $848,414 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
10,899 | $623,640 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
6,677 | $580,565 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
1,599 | $385,311 | |
| 8 | TGTX |
Tg Therapeutics, Inc.
|
6,261 | $343,979 |
All Filings in IKT
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $19,968 | 11,886 | Shares | Other | 2026-05-13 | |
| 2025-12-31 | $21,973 | 10,719 | Shares | Other | 2026-02-11 | |
| 2025-09-30 | $17,346 | 10,708 | Shares | Other | 2025-11-12 | |
| 2025-06-30 | $20,880 | 10,708 | Shares | Other | 2025-07-31 | |
| No filing history on record for this holder in this stock. | ||||||